Inhibition of the β-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids

References

• Gu P, Constantino L, Zhang Y. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide. J Med Microbiol 2008;57:1129–1134.
   PubMedGoogle Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199–229.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011;3:1165–1180.
   PubMed Web of Science ®Google Scholar
• Bertini I, Luchinat C, Scozzafava A. Interaction of cobalt-bovine carbonic anhydrase with the acetate ion. Biochim Biophys Acta 1976;452:239–244.
   PubMedGoogle Scholar
• Bertini I, Luchinat C, Scozzafava A. Binding affinity of bicarboxylate ions for cobalt (II) bovine carbonic anhydrase. Bioinorg Chem 1978;9:93–100.
   PubMedGoogle Scholar
• Håkansson K, Carlsson M, Svensson LA, Liljas A. Structure of native and apo carbonic anhydrase II and structure of some of its anion-ligand complexes. J Mol Biol 1992;227:1192–1204.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34.
   PubMed Web of Science ®Google Scholar
• Schlicker C, Hall RA, Vullo D, Middelhaufe S, Gertz M, Supuran CT et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol 2009;385:1207–1220.
   PubMed Web of Science ®Google Scholar
• Suarez Covarrubias A, Larsson AM, Högbom M, Lindberg J, Bergfors T, Björkelid C et al. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J Biol Chem 2005;280:18782–18789.
   PubMed Web of Science ®Google Scholar
• Covarrubias AS, Bergfors T, Jones TA, Högbom M. Structural mechanics of the pH-dependent activity of β-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem 2006;281:4993–4999.
   PubMed Web of Science ®Google Scholar
• Minakuchi T, Nishimori I, Vullo D, Scozzafava A, Supuran CT. Molecular cloning, characterization, and inhibition studies of the Rv1284 β-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J Med Chem 2009;52:2226–2232.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new β-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem 2009;52:3116–3120.
   PubMed Web of Science ®Google Scholar
• Güzel O, Maresca A, Scozzafava A, Salman A, Balaban AT, Supuran CT. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial β-carbonic anhydrases Rv1284 and Rv3273. J Med Chem 2009;52:4063–4067.
   PubMed Web of Science ®Google Scholar
• Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, Supuran CT. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. Bioorg Med Chem Lett 2009; 19:6649–6654.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Maresca A, Carta F, Scozzafava A, Supuran CT. The ß-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr Pharm Des 2010;16:3300–3309.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146–189.
   PubMed Web of Science ®Google Scholar
• Winum JY, Köhler S, Supuran CT. Brucella carbonic anhydrases: new targets for designing anti-infective agents. Curr Pharm Des 2010;16:3310–3316.
   PubMed Web of Science ®Google Scholar
• Vullo D, Nishimori I, Minakuchi T, Scozzafava A, Supuran CT. Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg Med Chem Lett 2011;21:3591–3595.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Onishi S, Takeuchi H, Supuran CT. The α and β classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008;14:622–630.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms. Mol Divers 2011;15:305–316.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467–3474.
   PubMed Web of Science ®Google Scholar
• Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009;7:81–87.
   PubMed Web of Science ®Google Scholar
• Furtado GH, Nicolau DP. Overview perspective of bacterial resistance. Expert Opin Ther Pat 2010;20:1273–1276.
   PubMed Web of Science ®Google Scholar
• Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008;29:552–559.
   PubMed Web of Science ®Google Scholar
• Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb) 2008;88 Suppl 1:S3–17.
   Google Scholar
• Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med 2008;2:455–471.
   PubMedGoogle Scholar
• Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–3062.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–2573.
   PubMed Web of Science ®Google Scholar
• Kolayli S, Karahalil F, Sahin H, Dincer B, Supuran CT. Characterization and inhibition studies of an α-carbonic anhydrase from the endangered sturgeon species Acipenser gueldenstaedti. J Enzyme Inhib Med Chem 2011;26:895–900.
   PubMed Web of Science ®Google Scholar
• Baranauskiene L, Hilvo M, Matuliene J, Golovenko D, Manakova E, Dudutiene V et al. Inhibition and binding studies of carbonic anhydrase isozymes I, II and IX with benzimidazo[1,2-c][1,2,3]thiadiazole-7-sulphonamides. J Enzyme Inhib Med Chem 2010;25:863–870.
   PubMed Web of Science ®Google Scholar
• Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003;48:77–84.
   PubMed Web of Science ®Google Scholar
• Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002;43:717–731.
   PubMed Web of Science ®Google Scholar
• Carta F, Innocenti A, Hall RA, Mühlschlegel FA, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives. Bioorg Med Chem Lett 2011;21:2521–2526.
   PubMed Web of Science ®Google Scholar
• Innocenti A, Hall RA, Schlicker C, Mühlschlegel FA, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates. Bioorg Med Chem 2009;17:2654–2657.
   PubMed Web of Science ®Google Scholar